Glaxo Group Limited

Smithkline Beecham Corporation

Glaxo Wellcome Inc.

Frank Ellis

Stephen Swanson

Brian Cox

Alan Naylor

Hazel Joan Dyke

David E Bays

George B Ewan

Christopher J Wallis

Chuen Chan

Caroline Mary Cook

Richard Peter Charles Cousins

Joanna Victoria Geden

Michael Gregson

Ian Waterhouse

Barry Edward Ayres, Deceased

John Knight

Alexander W Oxford

Peter C North

Suzanne Elaine Keeling

Colin David Eldred

Alison Judith Redgrave

David Hartley

David George Allen

Caroline Whitworth

Heather Hobbs

Andrew Michael Pennell

Richard Peter Charles

Terence Aaron Panchal

Simon Charles Dolan

Jason William Cooke

Roger Dansey

There are disclosed according to the invention, compounds of formula (I) wherein R , R and R are defined in the specification. Additionally, processes of preparing the compounds of formula (I), formulations containing same, and the administration of said compounds or formulations thereof in the treatment of inflammatory diseases are also disclosed.

2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.

2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives

Adenosine derivatives

Benzofurans and benzopyrans as chronobiological agents

2,6-Di (substitutedamino) purine ribonucleoside analogues and

The present invention relates to compounds of formula (IV): ##STR1## wherein R.sup.a and R.sup.b each represent a hydrogen atom or together form an alkylidene group.

2-6-diaminopurine precursors

Triazine derivatives of formula (I) ##STR1## or salts thereof, wherein

Chemical compounds

Compounds of formula (I) ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen, halogen, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, phenylC.sub.1-3 alkoxy (in which the phenyl group is optionally substituted by a substituent selected from halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy and hydroxy), nitro, trifluoromethyl, cyano, --CO.sub.2 R.sup.3 (wherein R.sup.3 is selected from hydrogen and C.sub.1-4 alkyl) and --CONR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 are each independently selected from hydrogen and C.sub.1-4 alkyl, or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached form a saturated 5- to 7- membered ring, which ring optionally contains one or more groups or atoms selected from oxygen, sulphur, --NH-- and --N(CH.sub.3)--); and R.sup.2 is selected from the group consisting of hydrogen, halogen, hydroxy, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; and salts thereof are inhibitors of the enzyme 5-lipoxygenase. Processes for preparing the compounds of formula (I) and compositions containing them are also described.

Triazine derivatives

Compounds of the formula (I) ##STR1## (in which X represents HS-- or a group R.sub.1 R.sub.2 N-- wherein R.sub.1 and R.sub.2 which may be the same or different represent hydrogen or a straight or branched chain alkyl group containing from 1 to 4 carbon atoms or a benzyl group and R.sub.3 represents a C.sub.3-7 alkyl group or a C.sub.3-7 cycloalkyl group) are prepared by reacting an .alpha.-ketoester of the formula (II) ##STR2## (in which Alk represents an alkyl group) or a precursor thereof with a compound of the formula (III) ##STR3## The precursor of the compound of formula (II) may be a mixture of isomeric enol esters ##STR4## The compounds of formula (I) may be converted into compounds of formula VIII ##STR5## in which R.sub.1 and R.sub.2 which may be the same or different represent hydrogen or a straight or branched chain alkyl group containing from 1 to 4 carbon atoms, and R.sub.3 is as defined above.

Production of triazinones

Growing community of inventors

Stevenage, United Kingdom

Frank Ellis